MEDICENNA THERAPEUTICS CORP/ CA58490H1073 /
9/20/2024 10:00:00 PM | Chg. -0.05 | Volume | Bid10:10:10 PM | Ask10:10:10 PM | High | Low |
---|---|---|---|---|---|---|
2.03CAD | -2.40% | 24,875 Turnover: 50,761 |
2.01Bid Size: 1,000 | 2.11Ask Size: 5,000 | 2.09 | 2.01 |
GlobeNewswire
8/27
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
GlobeNewswire
8/1
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder...
GlobeNewswire
6/27
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
GlobeNewswire
6/26
Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1...
GlobeNewswire
6/3
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Tre...
GlobeNewswire
5/31
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response w...
GlobeNewswire
5/22
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...
GlobeNewswire
4/24
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ...
GlobeNewswire
4/10
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation a...
GlobeNewswire
4/9
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation a...
GlobeNewswire
4/9
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-fun...
GlobeNewswire
4/4
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
3/6
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Associat...
GlobeNewswire
2/14
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
GlobeNewswire
2/13
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (...
GlobeNewswire
1/9
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
GlobeNewswire
11/17/2023
Delisting of Securities of Genesis Growth Tech Acquisition Corp.; Financial Strategies Acquisition C...
GlobeNewswire
11/17/2023
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Gliob...
GlobeNewswire
11/14/2023
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highligh...